Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio para identificar y describir factores predictores de eventos tromboembólicos en pacientes con policitemia vera de alto riesgo (Prospero)

22 de septiembre de 2026 actualizado por: Novartis Pharmaceuticals

Estudio observacional prospectivo para identificar y describir factores predictivos de eventos tromboembólicos en pacientes con policitemia vera de alto riesgo

This is a prospective observational study that will enroll patients with high-risk Polycythemia Vera (PV) with at least one Thromboembolic Event (TE) after diagnosis or up to 2 years prior to diagnosis.

This is a non-randomized study, and to ensure a sufficient number of patients in both cohorts, enrollment in each cohort will be terminated once the target of 150 patients has been reached.

Descripción general del estudio

Estado

Activo, no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

All patients are already on treatment with hydroxyurea or ruxolitinib at enrollment as per clinical practice and independently of their participation in this study. In addition, the follow-up visits and the evaluation procedures required in the study protocol correspond to current clinical practice. According to local regulations related to observational studies, assessments such as blood tests are justified by the purpose and rationale of the study (i.e., the identification of possible predictive factors of TEs) and are considered current clinical practice. Data related to other procedures will be collected only if such procedures are performed as per clinical practice but are not required otherwise.

Patients in both cohorts will be followed for 3 years after enrollment and will have visits at Months 6, 12, 18, 24, 30 and 36. A time window of ± 1 month is permitted for all visits.

Tipo de estudio

De observación

Inscripción (Actual)

242

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Naples, Italia, 80131
        • Novartis Investigative Site
    • AL
      • Alessandria, AL, Italia, 15121
        • Novartis Investigative Site
    • AN
      • Ancona, AN, Italia, 60020
        • Novartis Investigative Site
    • BA
      • Bari, BA, Italia, 70124
        • Novartis Investigative Site
    • BO
      • Bologna, BO, Italia, 40138
        • Novartis Investigative Site
    • CO
      • Como, CO, Italia, 22100
        • Novartis Investigative Site
    • CS
      • Cosenza, CS, Italia, 87100
        • Novartis Investigative Site
    • CT
      • Catania, CT, Italia, 95123
        • Novartis Investigative Site
    • FI
      • Florence, FI, Italia, 50134
        • Novartis Investigative Site
    • GE
      • Genova, GE, Italia, 16132
        • Novartis Investigative Site
    • LE
      • Lecce, LE, Italia, 73100
        • Novartis Investigative Site
      • Tricase, LE, Italia, 73039
        • Novartis Investigative Site
    • MB
      • Monza, MB, Italia, 20900
        • Novartis Investigative Site
    • MI
      • Milan, MI, Italia, 20122
        • Novartis Investigative Site
    • PA
      • Palermo, PA, Italia, 90127
        • Novartis Investigative Site
      • Palermo, PA, Italia, 90146
        • Novartis Investigative Site
    • PC
      • Piacenza, PC, Italia, 29121
        • Novartis Investigative Site
    • PD
      • Padova, PD, Italia, 35128
        • Novartis Investigative Site
    • PI
      • Pisa, PI, Italia, 56126
        • Novartis Investigative Site
    • PR
      • Parma, PR, Italia, 43126
        • Novartis Investigative Site
    • RC
      • Reggio Calabria, RC, Italia, 89124
        • Novartis Investigative Site
    • RE
      • Reggio Emilia, RE, Italia, 42123
        • Novartis Investigative Site
    • RM
      • Roma, RM, Italia, 00168
        • Novartis Investigative Site
      • Roma, RM, Italia, 00161
        • Novartis Investigative Site
      • Roma, RM, Italia, 00189
        • Novartis Investigative Site
    • SA
      • Pagani, SA, Italia, 84016
        • Novartis Investigative Site
    • TO
      • Orbassano, TO, Italia, 10043
        • Novartis Investigative Site
      • Torino, TO, Italia, 10126
        • Novartis Investigative Site
    • TR
      • Terni, TR, Italia, 05100
        • Novartis Investigative Site
    • VA
      • Varese, VA, Italia, 21100
        • Novartis Investigative Site
    • VI
      • Vicenza, VI, Italia, 36100
        • Novartis Investigative Site
    • VR
      • Verona, VR, Italia, 37134
        • Novartis Investigative Site
    • VT
      • Viterbo, VT, Italia, 01033
        • Novartis Investigative Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 99 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

The study will involve patients in Italy with high-risk Polycythemia Vera

Descripción

Inclusion Criteria:

  1. Signed informed consent must be obtained prior to participation in the study.
  2. Age ≥18 years.
  3. Diagnosis of PV according to WHO 2008 or WHO 2016 and high-risk stratification according to European LeukemiaNet (ELN) classification.
  4. At least one TE after diagnosis or up to 2 years prior to diagnosis.
  5. Patients on treatment with hydroxyurea at enrollment and for at least 18 months prior to enrollment or those on treatment with ruxolitinib who started treatment up to 18 months before enrollment.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Hydroxyurea

Patients being treated with hydroxyurea at enrollment and for at least 18 months prior to enrollment. Patients may switch to ruxolitinib treatment during the study in case of inadequate response or intolerance.

Prospective observational study. There is no treatment allocation. Patients prescribed with Hydroxyurea are eligible to enroll into this study.

Ruxolitinib

Patients on treatment with ruxolitinib who started treatment up to 18 months prior to enrollment.

Prospective observational study. There is no treatment allocation. Patients prescribed with Ruxolitinib are eligible to enroll into this study.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of abnormalities presented in patients with Thromboembolic Events (TEs) during the follow up
Periodo de tiempo: Up to 36 months

Demographics, blood pressure, laboratory blood tests, and use of antiplatelets and/or anticoagulants are predictors of TE occurrence, a univariate Cox regression model for repeated events will be applied for each predictor considering all the TEs occurring within 12 months and the time from baseline to each occurrence. Predictors found statistically significant at the 5% level will then be considered in a multivariate Cox regression model for repeated events.

Up to 36 months
Blood pressure
Periodo de tiempo: Up to month 36

Blood pressure is going to be collected

Up to month 36
Number of patients with abnormal Body Mass Index (BMI)
Periodo de tiempo: Up to month 36

Number of patients with abnormal Body Mass Index (BMI) will be collected

Up to month 36
Number of patients with abnormal weight
Periodo de tiempo: Up to month 36

Number of patients with abnormal weight will be collected

Up to month 36
Number of patients with abnormal Neutrophil (NEP) count
Periodo de tiempo: Up to 36 months

Number of patients with abnormal Neutrophil (NEP) count will be collected

Up to 36 months
Number of patients with abnormal White blood Count (WBC)
Periodo de tiempo: Up to 36 months

Number of patients with abnormal White blood Count (WBC) will be collected

Up to 36 months
Number of patients with abnormal Lymphocytes (LYP) count
Periodo de tiempo: Up to 36 months

Number of patients with abnormal Lymphocytes (LYP) count will be collected

Up to 36 months
Number of participants using antiplatelets and/or anticoagulants on the incidence of TEs
Periodo de tiempo: Up to 36 months

Number of participants using antiplatelets and/or anticoagulants on the incidence of Thromboembolic Events (TEs) will be collected

Up to 36 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Synergistic combinations of predictive factors
Periodo de tiempo: Up to 36 months

Synergistic combinations of predictive factors (Red cell Distribution Width, neutrophils, lymphocytes, neutrophil/ lymphocyte ratio and platelets).

Synergy score is defined as the product of the individual significances of variable 1 and 2 (expected) divided by the significance of the two-variable model (observed) To investigate cases of extreme synergy, instances in which two variables split the given cohort into high-risk and low-risk patients are far better than either variable alone. A simple synergy scoring metric to rank variable in terms of synergy (S):S12=(P1*P2)/P12 where P1 and P2 are the maximum possible (Cox regression derived) p-values for variable 1 and variable 2 and P12 was the max. p-value possible from the combination of variables 1 and 1. This synergy is intended to capture a variable that may provide exclusive non-redundant information when attempting to split a cohort based on risk and may provide an added insight into the functional/clinical rationale of a model

Up to 36 months
Yearly incidence of TEs
Periodo de tiempo: 36 months

Yearly incidence of Thromboembolic Events (TEs) will be collected

36 months
Incidence of arterial and venous TEs in the hydroxyurea and ruxolitinib cohorts
Periodo de tiempo: 36 months

Incidence of arterial and venous TEs in the hydroxyurea and ruxolitinib cohorts will be collected

36 months
Incidence and severity of adverse events
Periodo de tiempo: 36 months

Incidence and severity of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.

36 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

2 de marzo de 2023

Finalización primaria (Estimado)

31 de agosto de 2027

Finalización del estudio (Estimado)

31 de agosto de 2027

Fechas de registro del estudio

Enviado por primera vez

16 de septiembre de 2022

Primero enviado que cumplió con los criterios de control de calidad

16 de septiembre de 2022

Publicado por primera vez (Actual)

21 de septiembre de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

25 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

22 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir